FY2023 Earnings Estimate for Vaxart, Inc. Issued By Cantor Fitzgerald (NASDAQ:VXRT)

Vaxart, Inc. (NASDAQ:VXRT) – Cantor Fitzgerald raised their FY2023 earnings estimates for shares of Vaxart in a research report issued to clients and investors on Tuesday, November 14th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biotechnology company will earn ($0.56) per share for the year, up from their prior estimate of ($0.65). Cantor Fitzgerald has a “Overweight” rating and a $4.00 price objective on the stock. The consensus estimate for Vaxart’s current full-year earnings is ($0.68) per share. Cantor Fitzgerald also issued estimates for Vaxart’s FY2024 earnings at ($0.42) EPS.

Vaxart Stock Performance

NASDAQ:VXRT opened at $0.80 on Friday. The company has a market capitalization of $121.48 million, a PE ratio of -1.25 and a beta of 0.71. The company has a 50 day simple moving average of $0.71 and a two-hundred day simple moving average of $0.83. Vaxart has a fifty-two week low of $0.56 and a fifty-two week high of $1.59.

Institutional Trading of Vaxart

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cantor Fitzgerald L. P. bought a new position in shares of Vaxart during the 2nd quarter worth approximately $5,173,000. State Street Corp boosted its holdings in shares of Vaxart by 23.9% during the 1st quarter. State Street Corp now owns 13,860,974 shares of the biotechnology company’s stock worth $69,859,000 after buying an additional 2,673,332 shares in the last quarter. Two Sigma Investments LP boosted its holdings in shares of Vaxart by 217.1% during the 4th quarter. Two Sigma Investments LP now owns 2,634,716 shares of the biotechnology company’s stock worth $2,532,000 after buying an additional 1,803,720 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Vaxart by 1,862.7% during the 4th quarter. Millennium Management LLC now owns 1,693,090 shares of the biotechnology company’s stock worth $1,627,000 after buying an additional 1,606,826 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Vaxart during the 4th quarter worth approximately $972,000. Institutional investors and hedge funds own 19.04% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia.